Company Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 21, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Dr. Raju S. Mohan Ph.D. |
Contact Details
Address: 12790 El Camino Real, Suite 200 San Diego, California 92130 United States | |
| Phone | (858) 945-2393 |
| Website | ventyxbio.com |
Stock Details
| Ticker Symbol | VTYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001851194 |
| CUSIP Number | 92332V107 |
| ISIN Number | US92332V1070 |
| Employer ID | 83-2996852 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raju S. Mohan Ph.D. | Founder, Chief Executive Officer, President and Director |
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer |
| Dr. Martin Douglas Auster M.D. | Chief Financial Officer |
| Christopher W. Krueger J.D., MBA | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 6, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 1, 2024 | 424B3 | Prospectus |
| Apr 29, 2024 | EFFECT | Notice of Effectiveness |
| Apr 26, 2024 | EFFECT | Notice of Effectiveness |
| Apr 25, 2024 | ARS | Filing |